Test Price
2,800 AED✅ Home Collection Available
WDR81 Gene Cerebellar Ataxia, Intellectual Disability, and Dysequilibrium Syndrome Type 2 (CAMRQ2) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9 % Diagnostic Sensitivity via ISO 9001:2015‑accredited Next‑Generation Sequencing (NGS) with Sanger confirmation.
- Premium Logistics: Hospital‑grade home collection using ISO‑certified cold‑chain transport and VIP mobile phlebotomy (8 AM – 11 PM, daily).
- Clinical Guidance: Post‑test telephonic interpretation by a DHA‑licensed Consultant Medical Genetics specialist included.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This NGS‑based test screens the entire coding region of the WDR81 gene to confirm a molecular diagnosis of CAMRQ2, a rare autosomal recessive neurogenetic disorder characterized by cerebellar ataxia, intellectual disability, and dysequilibrium. Early confirmation enables precise neurological intervention, genetic counseling, and informed family planning. The methodology integrates whole‑exome capture with deep sequencing, followed by Sanger confirmation of all clinically significant variants.
| Feature | Our Test (DHA‑Accredited) | Closest Alternative |
|---|---|---|
| Methodology | NGS + Sanger Confirmation | Sanger sequencing of single exons |
| Turnaround Time | 3‑4 Weeks | 6‑8 Weeks |
| Price | 2800 AED | 3500‑4000 AED |
| Home Collection | Included (8 AM‑11 PM) | Limited or extra fee |
Physician Insight & Safety Protocols
“Every genetic variant tells a story. As a Consultant Medical Genetics specialist, I interpret your WDR81 result within the comprehensive context of your family history and clinical presentation. A molecular diagnosis of CAMRQ2 is not merely a label—it is the foundation for targeted intervention, prognostic counseling, and informed reproductive planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue any prescribed medication without consulting your treating physician. Genetic results have no immediate impact on ongoing drug regimens and must always be correlated with clinical status. Always consult your neurologist before making any changes to therapy.
Exclusion Criteria & Red Flags
- Exclusion Criteria: This test is not intended for prenatal diagnosis without formal genetic counseling; asymptomatic minors require parental consent and counseling, compliant with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: Seek emergency care immediately if the patient develops sudden worsening of balance, loss of consciousness, prolonged seizures, or respiratory distress after sample collection – these are unrelated to the blood draw but may indicate disease progression.
Patient FAQ & Clinical Guidance
1. What does a positive WDR81 mutation mean for my child?
Direct Answer: A positive result identifies a disease‑causing variant in WDR81, confirming a genetic predisposition to CAMRQ2 syndrome and guiding neurological care and family genetic counseling. It establishes the molecular basis of the condition, allowing targeted symptom management, educational support, and accurate recurrence‑risk estimates for future pregnancies. Your neurologist and genetic counselor will explain the prognosis based on the specific variant and clinical severity.
2. How should I prepare for the blood sample collection at home?
Direct Answer: No fasting or special preparation is needed; our DHA‑certified phlebotomist will collect a small venous blood sample from the arm using a cold‑chain kit. Simply ensure the patient is comfortable and well‑hydrated. A genetic counselling session to draw a pedigree chart will be arranged prior to the test. All steps are performed under strict infection‑control protocols compliant with UAE PDPL.
3. Is my genetic data secure and confidential under UAE law?
Direct Answer: Your genomic data is fully protected by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Samples are processed exclusively in a licensed facility and results are shared only with you and your designated physician through an encrypted portal. We never trade or share genetic data without explicit consent, and all reports are anonymized for research applications.
UAE Regulatory & Data Privacy Adherence
This test adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed under Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 Certificate: INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | WDR81 Gene Cerebellar Ataxia, Intellectual Disability, and Dysequilibrium Syndrome Type 2 (CAMRQ2) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G11.1, F70 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians